- Home
- LXFR vs LRMR Comparison
LXFR vs LRMR Comparison
Compare LXFR & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXFR | LRMR |
|---|---|---|
| Founded | 1898 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 459.5M | 455.8M |
| IPO Year | 2002 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LXFR | LRMR |
|---|---|---|
| Price | $17.22 | $3.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 382.5K | ★ 839.3K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $384,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.01 | $1,816.14 |
| P/E Ratio | $55.47 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.26 | $2.72 |
| 52 Week High | $19.45 | $6.42 |
Technical Indicators
Market Signals| Indicator | LXFR | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 46.11 |
| Support Level | $16.68 | $3.49 |
| Resistance Level | $17.38 | $4.20 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 21.95 | 29.79 |
Price Performance
Historical ComparisonAbout LXFR Luxfer Holdings PLC
Luxfer Holdings PLC is engaged in materials engineering and the manufacture of materials, components, and gas containment products. The company has two reportable segments: Elektron and Gas Cylinders. The Elektron segment produces specialty materials based on magnesium and zirconium for applications in aerospace, defense, automotive, and industrial markets. The Gas Cylinders segment manufactures high-pressure gas containment products using aluminum alloys and carbon composite technologies for use in healthcare, emergency response, aerospace, and alternative fuel transportation markets.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.